Premium
NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Recommendations for Gadolinium‐Based Contrast Use in Patients with Kidney Disease
Author(s) -
Perazella Mark A.,
Reilly Robert F.
Publication year - 2008
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2007.00402.x
Subject(s) - nephrogenic systemic fibrosis , medicine , nephrology , peritoneal dialysis , hemodialysis , kidney disease , intensive care medicine , dialysis , renal replacement therapy , disease , stage (stratigraphy) , gadolinium , radiology , paleontology , materials science , metallurgy , biology
Abstract Nephrogenic systemic fibrosis is a systemic disorder characterized by widespread tissue fibrosis. Gadolinium‐based contrast (GBC) was recently noted as a possible trigger for this disease. The vast majority of cases occur in patients with ESRD receiving hemodialysis or peritoneal dialysis. However, approximately 10% of cases develop in patients with AKI (many requiring dialysis), advanced CKD stage 4, and CKD stage 5 not receiving renal replacement therapy. Recommendations to guide the use of GBC in patients with underlying kidney disease are presented. These clinical practice guidelines should be individualized and considered in consultation with the ordering physician, radiologist, and nephrologist.